Medical Abortion: Action Needed to Ensure Compliance with Medicaid Drug Rebate Program

This GAO report examines how Medicaid programs across the U.S. handle coverage for mifepristone and Mifeprex, drugs approved for medical abortion. Despite federal requirements, the review found that some state programs still do not cover these medications or claim rebates as required, and oversight by CMS has lagged. The report urges immediate action to ensure compliance with the Medicaid Drug Rebate Program, highlighting gaps that affect access for eligible beneficiaries. With reproductive health and federal-state responsibilities under scrutiny, the findings stress the need for consistent enforcement and clearer guidance.